|
|
Volumn 94, Issue 23, 2002, Pages 1738-1739
|
|
For Bexxar, FDA meeting offers long-awaited chance at approval
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CD20 ANTIGEN;
IBRITUMOMAB TIUXETAN;
IODINE 131;
MONOCLONAL ANTIBODY LYM 1;
POLYCLONAL ANTIBODY;
RITUXIMAB;
TOSITUMOMAB I 131;
YTTRIUM 90;
B CELL LYMPHOMA;
CANCER RECURRENCE;
CANCER REGRESSION;
CANCER SURVIVAL;
DRUG APPROVAL;
DRUG CLEARANCE;
DRUG DOSE REGIMEN;
DRUG EFFICACY;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
MYELODYSPLASTIC SYNDROME;
NOTE;
PRIORITY JOURNAL;
RADIOIMMUNOTHERAPY;
|
|
EID: 0037021656
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/94.23.1738 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|